NEW YORK (GenomeWeb) – Interpace Diagnostics announced yesterday that the New York State Department of Health (NYSDOH) has approved its ThyraMir thyroid cancer classifier test.

ThyraMir analyzes the expression of 10 cancer-linked microRNAs to classify thyroid nodules as cancerous or benign following indeterminate results from fine-needle aspirate and biopsy samples. It is typically used in conjunction with Interpace's ThyGenX oncogene panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.